We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best blue chip stocks to buy under $100.

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks.

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 products by mimicking a hormone in the body that provides a satiated feeling, which curbs hunger, but adds a different hormone in the pancreas.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews